Free preview
MD Pharmacology NMC syllabus ~5 min read Recent advances last updated on 2026-05-18

Radioimmunoassay (RIA)

Principle, methodology, validation and applications of the prototype immunoassay — with the modern immunoassay/mass-spectrometry landscape.

Past RGUHS + DNB + MPMSU · 11 DNBDec '25 RGUHSDec '23 RGUHSJul '23 RGUHSNov '21 RGUHSJul '21 RGUHSNov '20 RGUHSNov '19 RGUHSMay '18 MPMSU2016 MPMSU2012 RGUHSOct '09

Introduction

  • Definition — Radioimmunoassay (RIA) is the original member of the immunoassay family — assays that use the specific molecular-recognition binding of antibodies (or receptors/ligands) to capture, detect and measure an analyte — distinguished by a radioactive label on the detection reagent.
  • Synonym — Immunoassays are equivalently termed ligand-binding assays (LBA); RIA is the radioisotopic prototype of this whole class.
  • Why it matters — Clinical pharmacology — therapeutic drug monitoring and drug development alike — depends on accurate measurement of drug/metabolite/biomarker concentrations; immunoassays are the principal platform for large molecules (proteins, monoclonal-antibody drugs).
  • Place among platforms — Small drug molecules → chromatographic methods (HPLC, LC-MS/MS); large therapeutics → immunoassays/LBA (the RIA family); RNA/DNA therapeutics → PCR assays.
Figure 1 — Analyte size sets the platform: small molecules → chromatography / LC-MS/MS, large therapeutics → immunoassay (the RIA family), nucleic-acid drugs → PCR
Figure 1 — Analyte size sets the platform: small molecules → chromatography / LC-MS/MS, large therapeutics → immunoassay (the RIA family), nucleic-acid drugs → PCR
Continue reading

Radioimmunoassay

PharmaNotes Pro · LAQ

Sign in with your Google account. If you're already subscribed, the chapter unlocks immediately — otherwise, pick Monthly or Annual on the next step.